Literature DB >> 8042985

Interaction of disintegrins with the alpha IIb beta 3 receptor on resting and activated human platelets.

M A McLane1, M A Kowalska, L Silver, S J Shattil, S Niewiarowski.   

Abstract

Viper venom disintegrins contain the RGD/KGD motif. They inhibit platelet aggregation and cell adhesion, but show structural and functional heterogeneity. We investigated the interaction of four prototypic disintegrins with alpha IIb beta 3 expressed on the surface of resting and activated platelets. The binding affinity (Kd) of 125I-albolabrin, 125I-echistatin, 125I-bitistatin and 125I-eristostatin toward resting platelets was 294, 153, 48 and 18 nM respectively. The Kd value for albolabrin decreased 3-fold and 6-fold after ADP- or thrombin-induced activation. The Kd values for bitistatin and echistatin also decreased with ADP, but there was no further decrease with thrombin. In contrast, eristostatin bound with the same high affinity to resting and activated platelets. The pattern of fluorescein isothiocyanate (FITC)-eristostatin and FITC-albolabrin binding to resting and activated platelets was consistent with observations using radiolabelled material. Eristostatin showed faster and more irreversible binding to platelets, and greater potency compared with albolabrin in inducing conformational neo-epitopes in beta 3. The anti-alpha IIb beta 3 monoclonal antibody OP-G2 that is RGD-dependent inhibited disintegrin binding to activated platelets more strongly than binding to resting platelets and it inhibited the binding to platelets of albolabrin more strongly than eristostatin. The specificity of disintegrin interaction with alpha IIb beta 3 was confirmed by demonstrating cross-linking of these peptides to alpha IIb beta 3 on normal platelets, but not to thrombasthenic platelets deficient in alpha IIb beta 3.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8042985      PMCID: PMC1137098          DOI: 10.1042/bj3010429

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  36 in total

Review 1.  Disintegrins: a family of integrin inhibitory proteins from viper venoms.

Authors:  R J Gould; M A Polokoff; P A Friedman; T F Huang; J C Holt; J J Cook; S Niewiarowski
Journal:  Proc Soc Exp Biol Med       Date:  1990-11

2.  Batroxostatin, an Arg-Gly-Asp-containing peptide from Bothrops atrox, is a potent inhibitor of platelet aggregation and cell interaction with fibronectin.

Authors:  B Rucinski; S Niewiarowski; J C Holt; T Soszka; K A Knudsen
Journal:  Biochim Biophys Acta       Date:  1990-09-24

3.  Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri.

Authors:  R M Scarborough; J W Rose; M A Hsu; D R Phillips; V A Fried; A M Campbell; L Nannizzi; I F Charo
Journal:  J Biol Chem       Date:  1991-05-25       Impact factor: 5.157

4.  Three-dimensional structure of echistatin, the smallest active RGD protein.

Authors:  V Saudek; R A Atkinson; J T Pelton
Journal:  Biochemistry       Date:  1991-07-30       Impact factor: 3.162

5.  Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex.

Authors:  P J Sims; M H Ginsberg; E F Plow; S J Shattil
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

6.  Elegantin and albolabrin purified peptides from viper venoms: homologies with the RGDS domain of fibrinogen and von Willebrand factor.

Authors:  J Williams; B Rucinski; J Holt; S Niewiarowski
Journal:  Biochim Biophys Acta       Date:  1990-05-31

7.  Agkistrodon piscivorus piscivorus platelet aggregation inhibitor: a potent inhibitor of platelet activation.

Authors:  B H Chao; J A Jakubowski; B Savage; E P Chow; U M Marzec; L A Harker; J M Maraganore
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

8.  Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms.

Authors:  J Musial; S Niewiarowski; B Rucinski; G J Stewart; J J Cook; J A Williams; L H Edmunds
Journal:  Circulation       Date:  1990-07       Impact factor: 29.690

9.  Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors.

Authors:  M S Dennis; W J Henzel; R M Pitti; M T Lipari; M A Napier; T A Deisher; S Bunting; R A Lazarus
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

10.  Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition site(s) on platelet glycoprotein IIb.IIIa complex inhibits receptor function.

Authors:  B Savage; U M Marzec; B H Chao; L A Harker; J M Maraganore; Z M Ruggeri
Journal:  J Biol Chem       Date:  1990-07-15       Impact factor: 5.157

View more
  13 in total

1.  Effect of the disintegrin eristostatin on melanoma-natural killer cell interactions.

Authors:  Stefan Hailey; Elizabeth Adams; Ryan Penn; Alice Wong; Mary Ann McLane
Journal:  Toxicon       Date:  2012-11-09       Impact factor: 3.033

2.  Differential recognition of snake venom proteins expressing specific Arg-Gly-Asp (RGD) sequence motifs by wild-type and variant integrin alphaIIbbeta3: further evidence for distinct sites of RGD ligand recognition exhibiting negative allostery.

Authors:  S Rahman; G Flynn; A Aitken; Y Patel; F Hussain; X Lu; J C Loftus; D French; E Wijelath; K Strand; G F Savidge
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

3.  The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.

Authors:  S Rahman; X Lu; V V Kakkar; K S Authi
Journal:  Biochem J       Date:  1995-11-15       Impact factor: 3.857

4.  Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins.

Authors:  C Marcinkiewicz; L A Rosenthal; D M Mosser; T J Kunicki; S Niewiarowski
Journal:  Biochem J       Date:  1996-08-01       Impact factor: 3.857

5.  Inhibition of melanoma cell motility by the snake venom disintegrin eristostatin.

Authors:  Jing Tian; Carrie Paquette-Straub; E Helene Sage; Sarah E Funk; Vivek Patel; Deni Galileo; Mary Ann McLane
Journal:  Toxicon       Date:  2007-01-10       Impact factor: 3.033

6.  An insight into the sialome of Glossina morsitans morsitans.

Authors:  Juliana Alves-Silva; José M C Ribeiro; Jan Van Den Abbeele; Geoffrey Attardo; Zhengrong Hao; Lee R Haines; Marcelo B Soares; Matthew Berriman; Serap Aksoy; Michael J Lehane
Journal:  BMC Genomics       Date:  2010-03-30       Impact factor: 3.969

7.  Platelet binding and biodistribution of [99mTc]rBitistatin in animal species and humans.

Authors:  Linda C Knight; Jan E Romano; Lewis T Bright; Alexis Agelan; Steven Kantor; Alan H Maurer
Journal:  Nucl Med Biol       Date:  2007-06-08       Impact factor: 2.408

8.  Foot-and-mouth disease virus forms a highly stable, EDTA-resistant complex with its principal receptor, integrin alphavbeta6: implications for infectiousness.

Authors:  Danielle Dicara; Alison Burman; Stuart Clark; Stephen Berryman; Mark J Howard; Ian R Hart; John F Marshall; Terry Jackson
Journal:  J Virol       Date:  2007-11-28       Impact factor: 5.103

Review 9.  Disintegrins from snake venoms and their applications in cancer research and therapy.

Authors:  Jéssica Kele Arruda Macêdo; Jay W Fox; Mariana de Souza Castro
Journal:  Curr Protein Pept Sci       Date:  2015       Impact factor: 3.272

10.  Functional transcriptomics of wild-caught Lutzomyia intermedia salivary glands: identification of a protective salivary protein against Leishmania braziliensis infection.

Authors:  Tatiana R de Moura; Fabiano Oliveira; Marcia W Carneiro; José Carlos Miranda; Jorge Clarêncio; Manoel Barral-Netto; Cláudia Brodskyn; Aldina Barral; José M C Ribeiro; Jesus G Valenzuela; Camila I de Oliveira
Journal:  PLoS Negl Trop Dis       Date:  2013-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.